UK markets open in 1 hour 7 minutes

AXA Framlington Biotech Z Inc (0P00015F8R.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
174.40+1.20 (+0.69%)
At close: 09:00PM BST

AXA Framlington Biotech Z Inc

7 Newgate Street

Management information
,Lead manager since 16 May 2023
Morningstar style box
Yahoo partners with Morningstar, a leading market research and investment data group to help investors rate and compare funds on Yahoo Finance. The Morningstar Category is shown next to the Morningstar Style Box, which identifies a fund's investment focus, based on the underlying securities in the fund.
https://s.yimg.com/lq/i/fi/3_0stylelargeeq6.gif
Morningstar category
While the investment objective stated in a fund's prospectus may or may not reflect how the fund actually invests, the Morningstar category is assigned based on the underlying securities in each portfolio. Morningstar categories help investors and investment professionals make meaningful comparisons between funds. The categories make it easier to build well-diversified portfolios, assess potential risk and identify top-performing funds. We place funds in a given category based on their portfolio statistics and compositions over the past three years. If the fund is new and has no portfolio history, we estimate where it will fall before giving it a more permanent category assignment. Where necessary, we may change a category assignment based on recent changes to the portfolio.

Fund overview

CategoryN/A
Fund familyAXA Investment Managers UK Ltd
Net assetsN/A
YTD return4.52%
Yield0.00%
Morningstar rating★★★★★
Inception date19 Jan 2015

Fund operations

Last dividendN/A
Last cap gainN/A
Holdings turnover88.00%
Average for categoryN/A

Fees and expenses

Expense0P00015F8R.LCategory average
Annual report expense ratio (net)0.00%N/A
Prospectus net expense ratio0.00%N/A
Prospectus gross expense ratio0.00%N/A
Max 12b1 feeN/AN/A
Max front end sales loadN/AN/A
Max deferred sales loadN/AN/A
3-yr expense projection0N/A
5-yr expense projection0N/A
10-yr expense projection0N/A